AMDL terminates Asian distribution deal
This article was originally published in Clinica
Executive Summary
Theranostics company AMDL is exercising its right to terminate its distribution agreement for DR-70 cancer blood test with Chinese Universal Technologies, as the Chinese company failed to meet its minimum purchase order of 10,000 during the initial year of the deal. Chinese Universal bought fewer than 400 kits, the Tustin, California-based company says.